Contact this trialFirst, we need to learn more about you.
Targeted Therapy
177Lu-DOTATATE for Advanced Breast Cancer
Recruiting1 awardPhase 2
Portland, Oregon
This trial is investigating whether 177Lu-DOTATATE can effectively treat breast cancer that has either spread to other parts of the body (stage IV) or come back after initial treatment (recurrent). 177Lu-DOTATATE works by targeting and destroying tumor cells that express the SSTR2 protein. This treatment is delivered through DOTATATE, which is linked to a radioactive agent called 177Lu. When DOTATATE comes in contact with tumor cells that express SSTR2, it delivers 177Lu to kill them. Researchers hope that giving 177Lu-DOTATATE to patients with SSTR2-positive breast cancer will shrink
Fill-in a few details and create your profileHaving a profile will help us send you recommended trials and speed up your application in the future.
We will keep your details privateWe won’t share unless you give us permission. By completing this form you agree to our privacy policy
Get in touch with the study teamWe’ll send your responses to the study team and help you to setup your first screening. This is not the start of informed consent. Screening happens between you and the trial.